AGREEMENT AND PLAN OF MERGER dated as of February 3, 2008 by and among PROGEN PHARMACEUTICALS LIMITED, PROGEN PHARMACEUTICALS, INC., CELLGATE, INC. and SPROUT CAPITAL IX, L.P., as RepresentativeAgreement and Plan of Merger • January 14th, 2009 • Progen Pharmaceuticals LTD • Medicinal chemicals & botanical products • Queensland
Contract Type FiledJanuary 14th, 2009 Company Industry JurisdictionThis AGREEMENT AND PLAN OF MERGER dated as of February 3, 2008 (this “Agreement”) is made and entered into by and among Progen Pharmaceuticals Limited, a company organized under the laws of Queensland, Australia (“Parent”), Progen Pharmaceuticals, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Sub”), CellGate, Inc., a Delaware corporation (the “Company”), and SPROUT CAPITAL IX, L.P., a Delaware limited partnership (the “Representative”), solely with respect to Article II hereof and such other provisions hereof which specifically refer to such Representative.
AGREEMENT AND PLAN OF MERGER dated as of February 3, 2008 by and among PROGEN PHARMACEUTICALS LIMITED, PROGEN PHARMACEUTICALS, INC., CELLGATE, INC. and SPROUT CAPITAL IX, L.P., as RepresentativeAgreement and Plan of Merger • January 13th, 2009 • Progen Pharmaceuticals LTD • Medicinal chemicals & botanical products • Queensland
Contract Type FiledJanuary 13th, 2009 Company Industry JurisdictionThis AGREEMENT AND PLAN OF MERGER dated as of February 3, 2008 (this “Agreement”) is made and entered into by and among Progen Pharmaceuticals Limited, a company organized under the laws of Queensland, Australia (“Parent”), Progen Pharmaceuticals, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Sub”), CellGate, Inc., a Delaware corporation (the “Company”), and SPROUT CAPITAL IX, L.P., a Delaware limited partnership (the “Representative”), solely with respect to Article II hereof and such other provisions hereof which specifically refer to such Representative.